positive
2 days agoSun Pharma’s Q2 results show consistent performance across domestic and global markets
Sun Pharmaceutical Industries posted a consolidated revenue of ₹14,478 crore for Q2 FY25-26, marking an 8% year-on-year increase. Net profit climbed 3% to ₹3,137 crore, while gross profit improved 14% to ₹3,798 crore. The company’s India business continued to contribute significantly, supported by its specialty portfolio and US generics. Analysts noted that despite pricing pressures in international markets, Sun maintained stable margins through cost control and product diversification. The company emphasized ongoing investments in specialty drugs and biosimilars for future growth.
positive
2 days agoSun Pharma’s Q2 results show consistent performance across domestic and global markets
Sun Pharmaceutical Industries posted a consolidated revenue of ₹14,478 crore for Q2 FY25-26, marking an 8% year-on-year increase. Net profit climbed 3% to ₹3,137 crore, while gross profit improved 14% to ₹3,798 crore. The company’s India business continued to contribute significantly, supported by its specialty portfolio and US generics. Analysts noted that despite pricing pressures in international markets, Sun maintained stable margins through cost control and product diversification. The company emphasized ongoing investments in specialty drugs and biosimilars for future growth.
2 days ago
1 min read
81 words
Sun Pharma’s Q2 results highlight steady operational growth with ₹14,478 crore revenue, 8% YoY rise, and improved profitability driven by strong specialty and generics portfolios across geographies.
Sun Pharmaceutical Industries posted a consolidated revenue of ₹14,478 crore for Q2 FY25-26, marking an 8% year-on-year increase. Net profit climbed 3% to ₹3,137 crore, while gross profit improved 14% to ₹3,798 crore. The company’s India business continued to contribute significantly, supported by its specialty portfolio and US generics. Analysts noted that despite pricing pressures in international markets, Sun maintained stable margins through cost control and product diversification. The company emphasized ongoing investments in specialty drugs and biosimilars for future growth.
Sun Pharmaceutical Industries posted a consolidated revenue of ₹14,478 crore for Q2 FY25-26, marking an 8% year-on-year increase. Net profit climbed 3% to ₹3,137 crore, while gross profit improved 14% to ₹3,798 crore. The company’s India business continued to contribute significantly, supported by its specialty portfolio and US generics. Analysts noted that despite pricing pressures in international markets, Sun maintained stable margins through cost control and product diversification. The company emphasized ongoing investments in specialty drugs and biosimilars for future growth.
Companies:
Sun Pharmaceutical Industries
Tags:
stocks
sun pharma
stocks
sun pharma
q2 results
earnings
pharma
Nov 6, 2025 • 04:50 IST